RELEVANT EVENT

Pursuant to the provisions of article 228 of the Consolidated Text of the Securities Market Act, approved by the Legislative Royal Decree 4/2015, of 23 October, Grifols, S.A. ("Grifols") hereby informs about the following:

1. Grifols has earned the approval from the U.S. Food and Drug Administration ("FDA") for its new genetic test to detect alpha-1 antitrypsin deficiency. This is the first time a U.S. health authority has approved molecular biology testing on DNA to detect a patient’s illness.

The A1AT Genotyping test, developed by Progenika Biopharma, a Grifols subsidiary with headquarters in Bilbao, is capable of simultaneously analyzing 99% of the most prevalent known mutations causing alpha-1 antitrypsin deficiency. This test has also had the CE marking since December 2016.

2. The European Medicines Agency (EMA) has approved a new product developed by Grifols: a biological sealant composed of fibrinogen and human thrombin to use in surgical operations in adults. This product obtained the FDA's approval on 1 November 2017, as reported in Relevant Event number 258231.

The biological sealant will be manufactured at Grifols' industrial complex located in Parets del Vallés (Barcelona, Spain).

In Barcelona, on 17 November 2017

______________________________
Nuria Martín Barnés
Secretary to the Board of Directors